Organising Committee

Gabriela MösleinGabriela Möslein (Chair/Secretary)

Surgical training in a non-University Hospital. Stipend in Japan with Professor Utsunomiya for pouch surgery. Establishment of a Polyposis Registry at University of Heidelberg. Surgical specialization, University of Heidelberg and Dusseldorf. DFG-Stipend at Mayo Clinic (Molecular Genetics with S. Thibodeau). Department Head of Visceral Surgery & Coloproctology 2005-15. Establishment of the Department for Hereditary Tumors, HELIOS Klinikum Wuppertal and University of Witten-Herdecke in 2015.


John BurnSir John Burn

MD FRCP FRCPE FRCPCH FRCOG FMedSci. Professor of Clinical Genetics, Newcastle University, Newcastle upon Tyne, UK. Consultant Clinical Geneticist in the Northern Genetics Service since 1984, Professor of Clinical Genetics, Newcastle University, over 400 publications. Knighted for services to Medicine and Healthcare 2010. Chief Investigator CaPP, the international Cancer Prevention Programme, which has shown aspirin can prevent hereditary colorectal cancer. Conceived and helped create the Millennium Landmark Centre for Life. Former chair British Society for Genetic Medicine, and of European Society of Human Genetics. Senior Investigator, National Institute Health Research. Director Collaborative Group for Genetics in Healthcare and chair of Department of Health Rare Disorders Databases and Registries Advisory Group. Non-executive director NHS England.


Photo of Gabriel CapelláGabriel Capellá

Gabriel Capellá obtained his MD degree by the University of Barcelona in 1983. He trained as a general and digestive surgeon at the Hospital de Sant Pau, Barcelona. His interest in translational cancer research lead him to a postdoctoral stay with Dr Manuel Perucho in 1989 and 1990. Back in Spain, he spent 8 years at the Gastrointestinal Research Laboratory at the Hospital de Sant Pau where he focused his research in the molecular basis of pancreatic and colorectal cancer. Since 1998 he has worked at the Instituto Catalán de Oncología where he was Director of the Translational Research Laboratory until 2011. Since 2010 he has served as Director of the Hereditary Cancer Program. His main interest is the study of the genetic basis of gastrointestinal cancer focusing in novel technologies for the clinical management of patient at risk of developing GI Cancer. He is co-author of more than 220 publications in international peer-reviewed journals. Since 2013 he has served as Vice-Director for Research and Innovation, Health Department, Catalan Government. He is co-founder of VCN Biosciences, a spin-off aimed at developing new cancer therapies based on oncolytic adenoviruses.


Ian FraylingIan Frayling

MA MB BChir PhD FRCPath FEBLM. Ian qualified in Clinical Medicine at Cambridge and after initial training in pathology he studied DNA damage repair for his PhD. In 1993, he was appointed Clinical Research Fellow in the Family Cancer Clinic at St Mark’s Hospital. There he helped to establish APC testing in familial polyposis and microsatellite instability testing in Lynch syndrome. He also helped identify the CRAC1 locus [now known to be GREM1] responsible for HMPS, and establish that the position within APC of an inherited mutation is itself a major modifier of polyposis severity. His work now concentrates on mutation interpretation and systematic testing of incident cancers to identify hereditary cases, and he is also an assessor for the UK National External Quality Assessment Scheme in Immunohistochemistry. He is a founder member of InSiGHT, InSiGHT’s Variant Interpretation Committee, and the Mallorca Group. In 2015 he was elected to InSiGHT Council.


Maurizio GenuardiMaurizio Genuardi

Maurizio Genuardi is a clinical geneticist active in the field of inherited predisposition to cancer since 1986. He is Full Professor of Medical Genetics and Director of the Institute of Medical Genomics at the Catholic University, and Director of the Medical Genetics Services at the Policlinico Agostino Gemelli University Hospital in Rome. He is the current chairperson of InSiGHT (2015-2017), and will host the 2017 biennial meeting of the Society in Florence. He has chaired the Variant Interpretation Committee of InSiGHT since 2007, coordinating the initiative culminated in the classification of > 2,000 DNA variants in the Mismatch Repair genes (Thompson et al. Nat Genet 2014; 46:107-115). He has coordinated the Cancer Genetics Working Group of the Italian Society of Human Genetics (SIGU) in 2012-2015 and is the President Elect of SIGU for 2017-2019. He has organized, with Professor Dominique Stoppa-Lyonnet, the Clinical Cancer Genetics Workshops at the meetings of the European Society of Human Genetics since 2013.


Photo of Magnus von Knebel DoeberitzMagnus von Knebel-Doeberitz

Magnus von Knebel Doeberitz is Medical Director of the Department of Applied Tumor Biology at the Institute of Pathology, University Hospital Heidelberg and leads the Clinical Cooperation Unit G105 at the German Cancer Research Centre in Heidelberg. One of his major scientific interests relates to the immune biology of cancers triggered by MMR deficiency and the development of immune therapeutics and vaccines.


Pål MøllerPål Møller (Treasurer)

MD, PhD. Senior Scientist and Senior Consultant at the Department of Tumor Biology at the Norwegian Radium Hospital and Department of Medical Genetics at Oslo University Hospital. Specialist in medical genetics. Educated in dBASE, Delphi and Oracle programming to handle electronical patient files and research registries. Organized and chaired clinical genetic service in Norway from 1988. Participated in the Breast Cancer Linkage Consortium and Biomed Breast Cancer Demonstration Programme for identification of the breast cancer genes and use of BRCA testing, current member of ENIGMA. Participated in the ICG-HNPCC to identify the MMR genes causing Lynch syndrome, the forming of InSiGHT and the Mallorca group, and current member of the InSiGHT variant interpretation committee and the Human Variome Project. PI of the Prospective Lynch Syndrome Database to describe Lynch syndrome and effects of interventions.


Photo of Rolf SijmonsRolf Sijmons

Rolf Sijmons is consultant clinical geneticist with more than 25 years professional experience. He is Professor of Medical Translational Genetics at the Department of Genetics, University Medical Center Groningen, the Netherlands. His main clinical and research interests are familial and hereditary cancer, the clinical application of next-generation technology and applied informatics. He is one of the curators of the international InSiGHT database on mismatch repair (MMR) gene mutations (http://www.insight-group.org), member of the InSiGHT MMR UV interpretation committee, editor of the Familial Cancer Database (http://www.facd.info) and one of the three editors-in-chief of the journal Hereditary Cancer in Clinical Practice.

Top